Stock listing
NASDAQ:PEPG PepGen Inc. Stock
Home listing (NASDAQ) of PepGen Inc.
Follow PepGen Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:PEPG
$3.78 USD -0.05 (-1.3%)
Close on Nov 20, 2026
- Day range
- $3.69 – $3.98 USDNov 20, 2026
- Volume
- 4.43M sharesNov 20, 2026
- Market cap
- $261.8M USDAt the close on Nov 20, 2026 · price × 69.26M shares outstanding
- 52-week range
- $1.31 – $7.80 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $13.23M USDMedian day 782,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PEPG · Home | $3.78 USD | -0.05 (-1.3%) | 4,429,478 | $3.86 | $3.98 | $3.69 | $3.83 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PEPG · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $3.78 | -0.05 | -1.3% | $3.86 | $3.98 | $3.69 | 4,429,478 | |
| $3.83 | -0.05 | -1.3% | $4.15 | $4.21 | $3.735 | 3,386,571 | |
| $3.88 | -0.31 | -7.4% | $4.09 | $4.20 | $3.615 | 5,606,468 | |
| $4.19 | -0.17 | -3.9% | $4.27 | $4.34 | $4.105 | 2,606,674 | |
| $4.36 | -0.68 | -13.5% | $5.05 | $5.05 | $4.34 | 5,890,927 | |
| $5.04 | -0.22 | -4.2% | $5.26 | $5.35 | $4.84 | 12,026,554 | |
| $5.26 | +0.65 | +14.1% | $5.40 | $5.90 | $5.105 | 16,011,177 | |
| $4.61 | +2.22 | +92.9% | $5.545 | $6.45 | $4.42 | 106,515,887 | |
| $2.39 | -0.08 | -3.2% | $2.52 | $2.52 | $2.28 | 1,376,439 | |
| $2.47 | +0.15 | +6.5% | $2.33 | $2.52 | $2.33 | 998,200 | |
| $2.32 | -0.13 | -5.3% | $2.55 | $2.55 | $2.22 | 958,800 | |
| $2.45 | -0.01 | -0.4% | $2.53 | $2.69 | $2.375 | 1,800,600 | |
| $2.46 | +0.11 | +4.7% | $2.36 | $2.485 | $2.36 | 612,500 | |
| $2.35 | -0.01 | -0.4% | $2.39 | $2.467 | $2.305 | 565,900 | |
| $2.36 | -0.05 | -2.1% | $2.40 | $2.405 | $2.22 | 1,129,000 | |
| $2.41 | -0.12 | -4.7% | $2.54 | $2.62 | $2.40 | 766,600 | |
| $2.53 | -0.07 | -2.7% | $2.58 | $2.64 | $2.485 | 767,800 | |
| $2.60 | +0.11 | +4.4% | $2.49 | $2.62 | $2.47 | 1,332,000 | |
| $2.49 | -0.03 | -1.2% | $2.51 | $2.675 | $2.46 | 906,900 | |
| $2.52 | -0.18 | -6.7% | $2.68 | $2.80 | $2.44 | 1,161,300 | |
| $2.70 | -0.02 | -0.7% | $2.71 | $2.83 | $2.65 | 1,041,900 | |
| $2.72 | -0.15 | -5.2% | $2.89 | $2.99 | $2.72 | 1,173,900 | |
| $2.87 | +0.17 | +6.3% | $2.66 | $2.94 | $2.62 | 2,761,600 | |
| $2.70 | +0.10 | +3.8% | $2.55 | $2.73 | $2.495 | 1,083,000 | |
| $2.60 | +0.07 | +2.8% | $2.56 | $2.69 | $2.50 | 1,199,500 | |
| $2.53 | +0.21 | +9.1% | $2.30 | $2.60 | $2.30 | 764,200 | |
| $2.32 | -0.18 | -7.2% | $2.44 | $2.49 | $2.26 | 917,300 | |
| $2.50 | +0.01 | +0.4% | $2.48 | $2.60 | $2.41 | 1,218,300 | |
| $2.49 | -0.13 | -5.0% | $2.61 | $2.61 | $2.48 | 315,800 | |
| $2.62 | +0.24 | +10.1% | $2.39 | $2.65 | $2.39 | 603,700 | |
| $2.38 | -0.02 | -0.8% | $2.38 | $2.447 | $2.28 | 844,600 | |
| $2.40 | +0.09 | +3.9% | $2.31 | $2.48 | $2.275 | 642,800 | |
| $2.31 | -0.05 | -2.1% | $2.38 | $2.385 | $2.26 | 590,200 | |
| $2.36 | +0.08 | +3.5% | $2.30 | $2.39 | $2.255 | 606,400 | |
| $2.28 | +0.07 | +3.2% | $2.24 | $2.31 | $2.225 | 744,400 | |
| $2.21 | -0.21 | -8.7% | $2.38 | $2.425 | $2.21 | 782,900 | |
| $2.42 | +0.08 | +3.4% | $2.34 | $2.525 | $2.34 | 2,149,500 | |
| $2.34 | -0.25 | -9.7% | $2.61 | $2.65 | $2.32 | 2,349,500 | |
| $2.59 | 0.00 | 0.0% | $2.55 | $2.645 | $2.46 | 740,000 | |
| $2.59 | -0.09 | -3.4% | $2.68 | $2.72 | $2.585 | 513,200 | |
| $2.68 | -0.04 | -1.5% | $2.71 | $2.715 | $2.63 | 657,400 | |
| $2.72 | -0.26 | -8.7% | $2.95 | $2.96 | $2.695 | 715,400 | |
| $2.98 | +0.14 | +4.9% | $2.84 | $3.03 | $2.82 | 523,500 | |
| $2.84 | -0.01 | -0.4% | $2.88 | $2.915 | $2.80 | 652,400 | |
| $2.85 | -0.12 | -4.0% | $2.97 | $2.98 | $2.835 | 580,400 | |
| $2.97 | +0.07 | +2.4% | $2.90 | $2.99 | $2.85 | 447,600 | |
| $2.90 | +0.01 | +0.3% | $2.92 | $2.975 | $2.85 | 613,200 | |
| $2.89 | -0.08 | -2.7% | $2.93 | $2.94 | $2.84 | 567,300 | |
| $2.97 | -0.01 | -0.3% | $2.99 | $3.10 | $2.91 | 718,400 | |
| $2.98 | -0.04 | -1.3% | $3.03 | $3.10 | $2.95 | 683,000 | |
| $3.02 | -0.13 | -4.1% | $3.13 | $3.13 | $3.00 | 972,800 | |
| $3.15 | -0.06 | -1.9% | $3.17 | $3.48 | $3.10 | 1,153,700 | |
| $3.21 | +0.10 | +3.2% | $3.06 | $3.24 | $2.91 | 1,929,700 | |
| $3.11 | -0.07 | -2.2% | $3.14 | $3.195 | $3.10 | 201,000 | |
| $3.18 | 0.00 | 0.0% | $3.18 | $3.25 | $3.10 | 514,300 | |
| $3.18 | +0.06 | +1.9% | $3.15 | $3.30 | $3.085 | 352,700 | |
| $3.12 | +0.13 | +4.3% | $2.95 | $3.165 | $2.91 | 461,800 | |
| $2.99 | -0.09 | -2.9% | $3.04 | $3.05 | $2.92 | 365,800 | |
| $3.08 | +0.01 | +0.3% | $3.05 | $3.13 | $2.98 | 484,900 | |
| $3.07 | -0.15 | -4.7% | $3.22 | $3.30 | $3.07 | 469,900 | |
| $3.22 | -0.205 | -6.0% | $3.41 | $3.41 | $3.11 | 952,000 | |
| $3.425 | +0.235 | +7.4% | $3.21 | $3.57 | $3.19 | 985,000 | |
| $3.19 | +0.05 | +1.6% | $3.14 | $3.23 | $3.04 | 482,700 | |
| $3.14 | +0.105 | +3.5% | $3.09 | $3.23 | $3.031 | 671,800 | |
| $3.035 | -0.015 | -0.5% | $3.04 | $3.18 | $3.03 | 969,500 |
- Ticker
- NASDAQ:PEPG
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
PepGen Announces Pricing of $125 Million Public Offering
Latest deck · Nov 10, 2026
Technical Presentation (November 2026)
Technical · 26 slides
Latest news
PepGen Announces Pricing of $125 Million Public Offering
Nov 11, 2026
Closed $5.04 (-4.2%) on Nov 12, 2026
PepGen Announces Proposed $125.0 Million Public Offering of Common Stock
Nov 10, 2026
Closed $5.26 (+14.1%) on Nov 11, 2026
PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
Nov 10, 2026
Closed $4.61 (+92.9%) on Nov 10, 2026
PepGen Announces Positive Phase 2 FREEDOM2-DM1 10 mg/kg Results Demonstrating Highest Reported Splicing Correction and Improvements Across Multiple Functional Measures
Nov 10, 2026
Closed $4.61 (+92.9%) on Nov 10, 2026
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Aug 6, 2026
Closed $2.41 (+21.7%) on Aug 6, 2026
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
Aug 6, 2026
Closed $2.41 (+21.7%) on Aug 6, 2026
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
May 21, 2026
Closed $1.54 (+6.9%) on May 21, 2026
PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
May 12, 2026
Closed $1.78 (+6.0%) on May 13, 2026
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data
Mar 30, 2026
Closed $4.23 (-6.4%) on Mar 30, 2026
PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights
Mar 4, 2026
Closed $6.76 (+5.3%) on Mar 4, 2026
PepGen Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 14 in the last 12 months · 86 in all · newest Nov 12, 2026 · oldest 2022
- Calls
- 1 call with a replay · 1 with a transcript · latest Mar 6, 2024
- Decks
- 18 decks · latest Nov 10, 2026
Where PepGen Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PEPG · Home listing · This page | NASDAQ | United States | USD |
| BOATS:PEPG | BOATS | United States | USD |
Valuation
Price/book 2.5× against a median of 1.2×: 9th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $172.6M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.5×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.11
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| PepGen Inc. · NASDAQ:PEPG | US$261.8M | US$172.6M | n/a | n/a | n/a | 2.5× | n/a | 0.1× | 1.11 |
| AgomAb Therapeutics NV · NASDAQ:AGMB | US$268.4M | −US$6.88M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.29 |
| Kyverna Therapeutics, Inc. · NASDAQ:KYTX | US$263.5M | US$117.8M | n/a | n/a | n/a | 2.0× | n/a | 0.2× | 2.02 |
| Ocugen, Inc. · NASDAQ:OCGN | US$260.6M | US$178.1M | n/a | 37.3× | n/a | n/a | n/a | n/a | 1.47 |
| Altimmune, Inc. · NASDAQ:ALT | US$258.8M | US$28.73M | n/a | n/a | n/a | 0.6× | n/a | 0.1× | 1.55 |
| Prelude Therapeutics Incorporated · NASDAQ:PRLD | US$258.6M | US$136.2M | n/a | 6.3× | n/a | 2.1× | −247.1% | 0.1× | 1.48 |
| OBI Pharma, Inc. · TPEX:4174 | US$258.4M | US$243.3M | n/a | 154× | n/a | 5.7× | n/a | 0.0× | n/a |
| TransThera Sciences (Nanjing). Inc. · HKEX:2617 | US$257.1M | US$119.1M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | n/a |
| Eikon Therapeutics, Inc. · NASDAQ:EIKN | US$256.8M | US$44.67M | n/a | n/a | n/a | 0.7× | n/a | 0.7× | 1.91 |
| SAB Biotherapeutics, Inc. · NASDAQ:SABS | US$255.7M | US$156.5M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.19 |
| Evommune, Inc. · NYSE:EVMN | US$255.5M | US$86.86M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | 0.96 |
| Median of the others | US$258.5M | US$118.5M | 37.3× | 1.2× | −247.1% | 0.0× | 1.48 |
Forecasts
7 strong buy · 1 sell · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 12.13 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.14 · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| James Mcarthur | President and Chief Executive Officer |
| Noel Donnelly | Chief Financial Officer |
| Emiko Bryant | Senior Vice President, HR and Administration |
| Hayley Parker | Senior Vice President, Global Regulatory Affairs & Quality |
| Paul Streck | Executive Vice President, Head of Research & Development |
| Christopher Abbott | Executive Director, CMC |
| Hongling Han | Executive Director, Analytical Development and QC |
| Joseph Vittiglio | Chief Business and Legal Officer |
| Kasra Kasraian | Chief Technical Officer |
| Melissa Michaels | Executive Director, Head of Regulatory Affairs CMC |
| Sarah Vacca | Executive Director, Clinical Operations |
Board
| Director | Role |
|---|---|
| Christopher Abbott | Executive Director, CMC |
| Habib Joseph Dable | Non-Executive Director |
| Heidi Henson | Non-Executive Director |
| Hongling Han | Executive Director, Analytical Development and QC |
| Howard Mayer | Non-Executive Director |
| Josh Resnick | Non-Executive Director |
| Lisa Wyman | Non-Executive Director |
| Melissa Michaels | Executive Director, Head of Regulatory Affairs CMC |
| Mitch Finer | Non-Executive Director |
| Sarah Vacca | Executive Director, Clinical Operations |
Events
Calls
| Call | When | Status |
|---|---|---|
| PepGen (NASDAQ:PEPG) Q4 2023 Earnings Call | Wed, Mar 06, 2024 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · Before open | +92.9% |
| Q2 2026 | Aug 6, 2026 · Before open | +21.7% |
| Q1 2026 | May 7, 2026 | −4.6% |
| Q4 2025 | Mar 4, 2026 · After close | −18.6% |
| Q3 2025 | Nov 12, 2025 · Before open | +10.3% |
| Q2 2025 | Aug 7, 2025 · Before open | −13.1% |
| Q1 2025 | May 8, 2025 · Before open | +22.2% |
| Q4 2024 | Feb 24, 2025 | +24.8% |
| Q3 2024 | Nov 7, 2024 · Before open | −21.7% |
| Q2 2024 | Aug 8, 2024 · Before open | +1.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · After close | −1.2% |
| Q4 2023 | Mar 6, 2024 · After close | −8.0% |
| Q3 2023 | Nov 8, 2023 · Before open | −10.4% |
| Q2 2023 | Aug 8, 2023 · Before open | +2.6% |
| Q1 2023 | May 11, 2023 · Before open | −2.9% |
| Q4 2022 | Mar 23, 2023 · After close | −9.8% |
| Q3 2022 | Nov 10, 2022 · Before open | +12.9% |
| Q2 2022 | Aug 12, 2022 · Before open | −6.7% |
| Q1 2022 | Jun 16, 2022 · Before open | +12.7% |
| Q4 2021 | Feb 11, 2022 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (November 2026) | Technical | 26 slides | Nov 10, 2026 |
| Investor Presentation (August 2026) | Investor deck | 29 slides | Aug 6, 2026 |
| Investor Presentation (August 2026) | Investor deck | 29 slides | August 2026 |
| Investor Presentation (May 2026) | Investor deck | 27 slides | May 21, 2026 |
| IDMC 2026 Late-Breaker | Conference | 19 slides | May 2026 |
| Corporate Update (March 2026) | Corporate update | 17 slides | Mar 30, 2026 |
| Investor Presentation (March 2026) | Investor deck | 20 slides | Mar 4, 2026 |
| OTS Annual Meeting 2025 | Conference | 17 slides | Oct 22, 2025 |
| Investor Presentation (October 2025) | Investor deck | 21 slides | Oct 1, 2025 |
| Technical Presentation (September 2025) | Technical | 18 slides | September 2025 |
All 18 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (May 2025) | Investor deck | 27 slides | May 28, 2025 |
| MDF Conference 2025 | Conference | 12 slides | May 2025 |
| Needham Conference 2025 | Conference | 33 slides | April 2025 |
| Technical Presentation (February 2025) | Technical | 24 slides | Feb 24, 2025 |
| Technical Presentation (July 2024) | Technical | 34 slides | Jul 30, 2024 |
| Technical Presentation (2024) | Technical | 9 slides | 2024 |
| Investor Presentation (March 2023) | Investor deck | 63 slides | Mar 27, 2023 |
| Corporate Update (September 2022) | Corporate update | 24 slides | Sep 28, 2022 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Update: US$125M · US$5 a share · Leerink Partners +4 Dealers: Leerink Partners (co-lead), Stifel (co-lead), Guggenheim Securities (co-lead), Oppenheimer & Co., H.C. Wainwright & Co. Use of proceeds: Fund ongoing clinical development of its product candidate, working capital and general corporate purposes | Nov 12, 2026 |
| Public offering of common stock Closed: US$115M raised · US$3.2 a share · Leerink Partners +1 Dealers: Leerink Partners (co-lead), Stifel (co-lead) Use of proceeds: Research and clinical development, including the FREEDOM-DM1 and FREEDOM2-DM1 trials, working capital and general corporate purposes | Sep 29, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$12.00 a share on May 5, 2022.
- Price
- US$12.00 a share
- Shares offered
- 9,000,000 shares of common stock
- Offering size
- US$108 million
- Underwriters' option
- Up to 1,350,000 more shares
- Underwriters
- BofA Securities, SVB Securities, Stifel, Wedbush PacGrow · In the order on the cover
- Shares delivered
- On or about May 10, 2022
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Oct 1, 2021 |
| Filed publicly | Apr 15, 2022 |
| Amended 3 times | Newest May 10, 2022 |
| Shares registered with an exchange | May 3, 2022 |
| Declared effective by the SEC | May 5, 2022 |
| Final prospectus, with the price | May 9, 2022 |
Filings
| Filing | Filed |
|---|---|
| EFFECT · Notice that a registration is effective | May 11, 2022 |
| POS AM · Amendment to an effective registration | May 10, 2022 |
| 424B4 · Prospectus | May 9, 2022 |
| EFFECT · Notice that a registration is effective | May 5, 2022 |
| CERT · Exchange's certificate of listing | May 5, 2022 |
| CORRESP · Letter to the SEC | May 4, 2022 |
| S-1/A · Registration statement, amended | May 4, 2022 |
| UPLOAD · Letter from the SEC | May 3, 2022 |
| 8-A12B · Registration of shares for listing on an exchange | May 3, 2022 |
| CORRESP · Letter to the SEC | May 3, 2022 |
All 23 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | May 3, 2022 |
| CORRESP · Letter to the SEC | May 2, 2022 |
| S-1/A · Registration statement, amended | May 2, 2022 |
| CORRESP · Letter to the SEC | Apr 22, 2022 |
| UPLOAD · Letter from the SEC | Apr 22, 2022 |
| S-1 · Registration statement | Apr 15, 2022 |
| DRSLTR · Letter to the SEC with a draft | Apr 8, 2022 |
| DRS/A · Draft registration statement, amended | Apr 8, 2022 |
| UPLOAD · Letter from the SEC | Mar 7, 2022 |
| DRSLTR · Letter to the SEC with a draft | Feb 11, 2022 |
| DRS/A · Draft registration statement, amended | Feb 11, 2022 |
| UPLOAD · Letter from the SEC | Oct 28, 2021 |
| DRS · Draft registration statement | Oct 1, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed May 9, 2022
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost of revenue | 1.40M | 1.50M | 1.18M | 493.0K | 178.0K | 110.0K | 106.0K |
| Gross profit | -1.40M | -1.50M | -1.18M | -493.0K | -178.0K | -110.0K | -106.0K |
| Research and development | 71.0M | 76.5M | 68.1M | 54.1M | 19.0M | 1.12M | 620.0K |
| Selling, general and administrative | 22.6M | 21.3M | 16.6M | 14.2M | 8.11M | 853.0K | 628.0K |
| Operating income | -93.6M | -97.7M | -84.8M | -68.3M | -27.1M | -1.88M | -1.35M |
| Depreciation and amortization | 1.40M | 1.50M | 1.20M | 500.0K | 200.0K | 110.0K | 106.0K |
| EBITDA | -92.2M | -96.2M | -83.6M | -67.8M | -26.9M | -1.77M | -1.25M |
| Interest expense | 3.40M | 172.0K | 8.00K | 0 | |||
| Income before tax | -89.6M | -90.6M | -78.6M | -65.4M | -27.3M | -1.89M | -1.35M |
| Income tax | 48.9K | -617.0K | 73.0K | 3.70M | 0 | -8.00K | |
| Net income | -89.7M | -90.0M | -78.6M | -69.1M | -27.3M | -1.89M | -1.35M |
| Earnings per share, basic | -2.12 | -2.85 | -3.30 | -4.42 | -30.27 | -0.08 | -0.06 |
| Earnings per share, diluted | -2.12 | -2.85 | -3.30 | -4.42 | -30.27 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 60.5M | 49.4M | 80.8M | 181.8M | 132.9M | 9.78M | 3.49M |
| Short-term investments | 87.9M | 70.8M | 29.6M | 0 | |||
| Receivables | 58.0K | 4.74M | 407.0K | 230.0K | |||
| Current assets | 151.0M | 123.8M | 112.7M | 186.1M | 140.0M | 10.3M | 3.77M |
| Property, plant and equipment | 1.90M | 3.72M | 4.76M | 3.33M | 636.0K | 323.0K | 419.0K |
| Total assets | 173.9M | 150.9M | 143.1M | 217.4M | 143.6M | 10.6M | 4.19M |
| Accounts payable | 822.0K | 1.75M | 1.00M | 1.36M | 3.24M | 721.0K | 141.0K |
| Current liabilities | 12.6M | 16.7M | 17.5M | 18.8M | 10.3M | 838.0K | 326.0K |
| Total debt | 17.0M | 18.7M | 20.1M | 24.5M | |||
| Total liabilities | 26.5M | 32.3M | 34.6M | 37.8M | 10.5M | 868.0K | 326.0K |
| Shareholders' equity | 147.4M | 118.6M | 108.4M | 179.6M | -32.1M | 9.77M | 3.87M |
| Shares outstanding | 68.9M | 32.6M | 23.8M | 23.7M | 963.6K | 22.4M | 22.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -81.6M | -82.4M | -69.0M | -59.3M | -22.6M | -1.65M | -885.0K |
| Capital spending | -264.0K | -497.0K | -2.60M | -3.75M | -500.0K | -8.00K | -29.0K |
| Free cash flow | -81.9M | -82.9M | -71.6M | -63.0M | -23.1M | -1.66M | -914.0K |
| Cash from investing | -15.2M | -37.7M | -32.0M | -3.75M | -500.0K | -8.00K | -29.0K |
| Cash from financing | 108.0M | 88.7M | -189.0K | 112.2M | 147.7M | 7.95M | 2.79M |
| Share buybacks | 114.9M | ||||||
| Change in cash | 11.1M | -31.4M | -100.9M | 48.9M | 124.6M | 6.29M | 1.88M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 12, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Nov 12, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Nov 10, 2026 | Offer document | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Jun 22, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | May 22, 2026 | Other filings | SEC |
| 8-K · Current report | May 21, 2026 | Current report | SEC |
| CORRESP · Letter to the SEC | May 19, 2026 | Other filings | SEC |
| S-3 · Registration statement | May 19, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Apr 28, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2026 | Meeting notice | SEC |
| UPLOAD · Letter from the SEC | Apr 17, 2026 | Other filings | SEC |
| DRS · Draft registration statement | Apr 15, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 30, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 11, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 4, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 4, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 4, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 4, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 8, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 3, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Oct 1, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 1, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 1, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 30, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 30, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 26, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Sep 25, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Sep 24, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 24, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 6, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 8-K · Current report | May 28, 2025 | Current report | SEC |
| 4 · Change in ownership | May 21, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 21, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Apr 25, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 31, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Mar 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 31, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 31, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 31, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 28, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 4, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 28, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Feb 24, 2025 | Offer document | SEC |
| 8-K · Current report | Feb 24, 2025 | Results | SEC |
| 10-K · Annual report | Feb 24, 2025 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 7, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 7, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 29, 2025 | Current report | SEC |
| 8-K · Current report | Dec 16, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| 8-K · Current report | Oct 8, 2024 | Current report | SEC |
| 8-K · Current report | Sep 19, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 20, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 20, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Aug 12, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 8-K · Current report | Jul 30, 2024 | Current report | SEC |
| 4 · Change in ownership | Jul 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Jul 9, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Jul 3, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 2, 2024 | Other filings | SEC |
| 8-K · Current report | Jul 2, 2024 | Current report | SEC |
| S-3 · Registration statement | Jun 28, 2024 | Offer document | SEC |
| 4 · Change in ownership | Jun 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 20, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 5, 2024 | Other filings | SEC |
| 4 · Change in ownership | May 17, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 17, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2024 | Results | SEC |
| DEFA14A · Additional proxy material | May 1, 2024 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 26, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 16, 2024 | Meeting notice | SEC |
| 4/A · Change in ownership, amended | Apr 9, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Apr 9, 2024 | Big-stake notice | SEC |
| 10-K/A · Annual report, amended | Mar 29, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 15, 2024 | Current report | SEC |
| 8-K · Current report | Mar 13, 2024 | Current report | SEC |
| 144 · Notice of proposed sale | Mar 12, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 11, 2024 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Mar 6, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 6, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 6, 2024 | Results | SEC |
| 8-K · Current report | Mar 4, 2024 | Current report | SEC |
| 4 · Change in ownership | Mar 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 20, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 13, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| 424B5 · Prospectus | Feb 7, 2024 | Offer document | SEC |
| 8-K · Current report | Feb 7, 2024 | Material contract | SEC |
| 4 · Change in ownership | Jan 17, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 17, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 17, 2024 | Current report | SEC |
| 8-K · Current report | Jan 8, 2024 | Current report | SEC |
| 8-K · Current report | Dec 18, 2023 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Dec 11, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 5, 2023 | Insider trade | SEC |
| 8-K · Current report | Nov 15, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Nov 14, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 14, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 8, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 8, 2023 | Results | SEC |
| 8-K · Current report | Oct 12, 2023 | Current report | SEC |
| 8-K · Current report | Sep 6, 2023 | Current report | SEC |
| 8-K · Current report | Sep 6, 2023 | Current report | SEC |
| 424B5 · Prospectus | Aug 8, 2023 | Offer document | SEC |
| 8-K · Current report | Aug 8, 2023 | Material contract | SEC |
| 10-Q · Quarterly report | Aug 8, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2023 | Results | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
This page holds 200 of 311 filings. Open Filings
Cap table
Built by 6ix from PepGen Inc.’s releases · as of Nov 4, 2026
- Common shares
- 69,261,282
- Fully diluted
- 69,261,282
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 69,261,282 | Nov 4, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 4, 2026 | 69,261,282 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Peter Kolchinsky Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Wave Life Sciences Ltd. (Director · Since at least Aug 14, 2015); Black Diamond Therapeutics, Inc. (Director · Jul 5, 2023 – Jul 5, 2023 · Past); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Research Alliance Corp II (Chief Executive Officer, Director · Mar 17, 2021 – Mar 17, 2021 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Solid Biosciences Inc. (Director · Dec 10, 2020 – Jan 11, 2024 · Past); POINT Biopharma Global Inc (Chief Executive Officer, Director · Jul 7, 2020 – Jun 29, 2021 · Past); Forma Therapeutics Holdings Inc (Director · Jun 18, 2020 – Jun 8, 2022 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 3, 2022 · Past); Synthorx Inc (Director · Dec 6, 2018 – Jan 23, 2020 · Past); Kala Bio, Inc. (Director · Oct 3, 2018 – Mar 13, 2020 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – Jun 19, 2018 · Past); KalVista Pharmaceuticals, Inc. (Director · Oct 12, 2017 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Jun 20, 2017 – Apr 2, 2020 · Past); Dicerna Pharmaceuticals Inc (Director · Jan 29, 2014 – Nov 27, 2019 · Past) | Director · Since at least May 5, 2022 |
| Rajeev M Shah Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past) | Director · Since at least May 5, 2022 |
| Habib Joseph Dable Other companies: Tyra Biosciences, Inc. (Director · Since at least Apr 16, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Relay Therapeutics, Inc. (Director · Since at least Nov 4, 2025); Day One Biopharmaceuticals Inc (Director · Since at least Jan 17, 2024); Blueprint Medicines Corp (Director · Since at least Jun 23, 2022); Jade Biosciences, Inc. (Director · Jul 10, 2023 – Jun 5, 2024 · Past); Albireo Pharma Inc (Director · Aug 8, 2022 – Mar 2, 2023 · Past); Acceleron Pharma Inc (CEO and President, Director · Jan 4, 2021 – Nov 19, 2021 · Past) | Director · Since at least Sep 20, 2022 |
| Mitchell H Finer Other companies: Turmeric Acquisition Corp (Director · Oct 15, 2020 – Oct 15, 2020 · Past); Oncorus Inc (Director · Oct 1, 2020 – Jun 23, 2022 · Past); Tcr2 Therapeutics Inc (Director · Feb 13, 2019 – Feb 13, 2019 · Past); Adverum Biotechnologies Inc (Director · May 11, 2016 – Jul 31, 2019 · Past); Bluebird bio Inc (Chief Scientific Officer · Jun 18, 2013 – Jun 1, 2015 · Past) | Director · Since at least Mar 27, 2025 |
| Heidi Henson Other companies: Perspective Therapeutics, Inc. (Director · Since at least Jun 1, 2023); Lisata Therapeutics, Inc. (Director · Since at least Sep 15, 2022); Pardes Biosciences Inc (Chief Financial Officer · Dec 23, 2021 – Aug 31, 2023 · Past); Kura Oncology, Inc. (Chief Financial Officer · Mar 6, 2015 – Jan 24, 2018 · Past) | Non-Executive Director · Since at least May 5, 2022 |
| Joshua Resnick Other companies: Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Cidara Therapeutics Inc (Director · Since at least Jan 3, 2025); Jade Biosciences, Inc. (Director · Jun 5, 2024 – Jun 5, 2024 · Past); Vor Biopharma Inc. (Director · May 23, 2024 – May 22, 2025 · Past) | Director · Since at least Jun 20, 2024 |
| Laurie Keating Other companies: Kalaris Therapeutics, Inc. (Director · Since at least Jul 6, 2026); Immuneering Corporation (Director · Since at least Jul 29, 2021); Imago Biosciences Inc (Director · Nov 17, 2021 – Jan 11, 2023 · Past); Alnylam Pharmaceuticals, Inc. (EVP, Chief Legal Officer · Jan 11, 2021 – Aug 5, 2021 · Past) | Director · Since at least May 5, 2022 |
| Joseph Vittiglio Other companies: Bluebird bio Inc (Chief Business & Legal Officer · Since at least Jan 3, 2023); AMAG Pharmaceuticals Inc (Chief Business Officer, GC · Aug 24, 2015 – Nov 16, 2020 · Past); AVEO Pharmaceuticals Inc (SVP, General Counsel · May 30, 2012 – Jan 6, 2015 · Past) | Chief Business and Legal Officer · Since at least Dec 8, 2025 |
| Howard Mayer Other companies: Invivyd, Inc. (Director · Aug 5, 2021 – Jun 22, 2022 · Past); Entasis Therapeutics Holdings Inc (Director · Aug 5, 2019 – Jul 7, 2022 · Past) | Non-Executive Director · Since at least Nov 10, 2023 |
| Josh Resnick Other companies: Sionna Therapeutics, Inc. (Director · Since at least Nov 4, 2026) | Non-Executive Director · Since at least Nov 4, 2026 |
All 31 people
| Person | Seat |
|---|---|
| Noel Donnelly Other companies: Radiopharm Theranostics Limited (Director · Since at least Mar 18, 2026) | Chief Financial Officer · Since at least May 5, 2022 |
| Christopher Abbott | Executive Director, CMC · Since at least Nov 4, 2026 |
| Christopher Ashton | Director · May 5, 2022 – Jun 20, 2024 · Past |
| Emiko Bryant | Senior Vice President, HR and Administration · Since at least Nov 4, 2026 |
| Hayley Parker | Senior Vice President, Global Regulatory Affairs & Quality · Since at least Nov 4, 2026 |
| Hongling Han | Executive Director, Analytical Development and QC · Since at least Nov 4, 2026 |
| James McArthur | President and Chief Executive Officer · Since at least May 5, 2022 |
| Jaya Goyal | EVP, Res. & Preclin. Dev. · May 5, 2022 – Mar 24, 2023 · Past |
| Kasra Kasraian | Chief Technical Officer · Since at least May 20, 2025 |
| Lisa Wyman | Director · Since at least Mar 27, 2025 |
| Mary Beth DeLena | General Counsel · Jan 15, 2024 – Mar 3, 2025 · Past |
| Melissa Michaels | Executive Director, Head of Regulatory Affairs CMC · Since at least Nov 4, 2026 |
| Michael Zhao | Vice President, Head of Biometrics · Nov 4, 2026 – Nov 4, 2026 · Past |
| Michelle L Mellion | Chief Medical Officer · May 5, 2022 – Jul 24, 2024 · Past |
| Mitch Finer | Non-Executive Director · Since at least Nov 4, 2026 |
| Niels Svenstrup | SVP, Chem. Mfg & Controls · May 5, 2022 – May 17, 2024 · Past |
| Pallavi Lonkar | Vice President, Head of Preclinical · Nov 4, 2026 – Nov 4, 2026 · Past |
| Paul Streck | EVP, Head of R&D · Since at least Aug 19, 2024 |
| Rod Lozano | Vice President, Information Technology · Nov 4, 2026 – Nov 4, 2026 · Past |
| Sarah Vacca | Executive Director, Clinical Operations · Since at least Nov 4, 2026 |
| Sonia Bracegirdle | See Remarks · May 5, 2022 – May 6, 2022 · Past |
Log in to ask 6ix AI your own questions about PepGen Inc.